Luke Huerter, MD
Hematology & Oncology · Lawrence, KSNPI 1861679276
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $780 of the $1,271 with a category attached, or 61.4%. Geron Corporation accounts for 61.4% of it on its own, with 4 other manufacturers making up the rest. 2025 is the largest year on record at $995, more than ten times the $15 reported in 2019. That places this record below the midpoint for hematology & oncology clinicians in KS, where the typical reported total is $1,410.
Across 12 payments — averaging $105.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Geron Corporation$780
- Seagen Inc.$200
- Merck$148
- AstraZeneca$128
- Puma Biotechnology, Inc.$15
What the payments were for
- Consulting fees$78061%
- Food & beverage$16613%
- Education$32526%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Geron Corporation | 1 | $780 |
| Seagen Inc. | 2 | $200 |
| Merck | 7 | $148 |
| AstraZeneca | 1 | $128 |
| Puma Biotechnology, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,271 in reported general payments places this provider in the 45th percentile of 97 hematology & oncology providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BrukinsaZanubrutinib | 24 | $372,437 |
| VenclextaVenetoclax | 16 | $226,373 |
| Lenalidomide | 15 | $211,049 |
| EliquisApixaban | 88 | $78,853 |
| XareltoRivaroxaban | 40 | $45,705 |
| Fentanyl | 23 | $2,068 |
| Abiraterone Acetate | 17 | $1,472 |
| Anastrozole | 91 | $1,230 |
| Oxycodone Hcl | 65 | $1,177 |
| Exemestane | 11 | $878 |
| Hydroxyurea | 48 | $863 |
| Tamoxifen Citrate | 41 | $812 |
| Potassium Chloride | 39 | $757 |
| Prochlorperazine Maleate | 51 | $668 |
| Morphine Sulfate ErMorphine Sulfate | 15 | $561 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Lawrence
- Sharon SouleLawrence$1K
- Shaker DakhilWichita$579K
- Quoc TruongWichita$539K
- Bassam MattarWichita$221K
- Marc HoffmannOverland Park$153K
- Priyanka SharmaWestwood$135K
- Jeffrey WeitzelKansas City$117K
- Joseph McGuirkKansas City$113K
- Gary DoolittleWestwood$102K
- Dhruv BansalOverland Park$79K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.